BRISTOL, UK: A University of Bristol spin-off has been awarded almost £1 million to bring a new technology to the market that could help to fight infections in the mouth and body. An enhanced form of chlorhexidine, the substance, named Pertinax, is said to offer improved properties compared with those of the original substance.
Overall, Pertinax Pharma has received around £900,000 from southern England technology investor Mercia Fund Management, Innovate UK (through its Aid for Start-Ups scheme) and an unnamed private investor. The company’s founder and chief scientific officer, Dr Michele Barbour, who is also a senior lecturer in biomaterials at the university’s School of Oral and Dental Sciences, said that the company will focus on the development of applications in dentistry first, where the technology already has relevance to a number of areas. Further uses in medicine will follow in time.
“We’re very excited about Pertinax’s potential,” she said.
A proven antimicrobial agent, chlorhexidine has been used in a wide range of products and treatment processes to prevent and treat bacterial infections. Since it is a new formulation of the substance, Pertinax is reported to possess the same antibacterial properties, but without some of the shortcomings of the original formulation, such as short efficacy time. Possible future applications are its use in cements to reduce the failure rates of dental fillings, for example.
“With a strong management team and innovative product, Pertinax Pharma has the potential to take its product from dental tool to a must-have anti-infective across a wide range of industries, from veterinary care, to cosmetics and even home appliances,” Investment Manager at Mercia Fund Management Dr Brijesh Roy commented.
Mercia Fund Management recently provided funding for another oral health care-related project by the University of Manchester.
CHARLOTTE, N.C., US/BRISTOL, UK: Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, has continued its ...
LONDON, UK: According to Western folklore, children with a wiggly primary tooth can look forward to a visit from the tooth fairy, making an otherwise ...
HARROGATE, England: Neoss Group has recently announced that it has obtained certification under Regulation (EU) 2017/745 (Medical Device Regulation—MDR) ...
CARDIFF, UK: Thanks to improved healthcare and living conditions, and a range of other factors, life expectancy in the UK has been increasing steadily in ...
BIRMINGHAM, UK: The link between periodontal disease and a range of systemic health conditions such as cardiovascular disease, Type 2 diabetes and ...
HARROGATE, UK: Dental implant solution provider Neoss has reported that it recently secured an investment deal with Yorkshire Bank in Leeds. The £1.5 ...
GUILDFORD, UK: Dental disease identification is often cumbersome and time-consuming. To assist dental professionals in better detecting dental problems, ...
MANCHESTER, UK/MELAKA, Malaysia: The use of sedatives, acupuncture or behavioural therapies are just some of the strategies recommended to dental ...
NEWCASTLE UPON TYNE – A new study, which was commissioned by the World Health Organization (WHO), has provided new evidence that the reduction of the ...
LONDON, UK: More than one-third of UK practice owners report that private revenue is higher now than it was before the pandemic, according to an insider ...
Live webinar
Mon. 28 April 2025
5:30 pm UTC (London)
Live webinar
Tue. 29 April 2025
4:00 pm UTC (London)
Live webinar
Tue. 29 April 2025
6:00 pm UTC (London)
Live webinar
Tue. 29 April 2025
8:00 pm UTC (London)
Prof. Dr. Patrick R. Schmidlin
Live webinar
Wed. 30 April 2025
12:30 pm UTC (London)
Live webinar
Thu. 1 May 2025
1:00 am UTC (London)
Live webinar
Sat. 3 May 2025
5:00 pm UTC (London)
Prof. Dr. Glen Liddelow BDSc(WA), MScD(WA), DClinDent(Syd), MRACDS(Pros), FAANZP, FPFA, FADI, FICD, FRACDS, Dr. Robert Gottlander DDS
To post a reply please login or register